In severe COVID-19, adding lopinavir–ritonavir to usual care did not improve mortality at 28 days

Abstract

SOURCE CITATION\nRECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52. 33031764.